Puma Biotechnology Inc - Company Profile
Powered by 
All the data and insights you need on Puma Biotechnology Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Puma Biotechnology Inc Strategy Report
- Understand Puma Biotechnology Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Puma Biotechnology Catalyst Calendar
Proactively evaluate Puma Biotechnology Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Puma Biotechnology Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 30 Jun 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 27 May 2020 | Phase II Trial Results | AbbVie Inc; Ambrx Biopharma Inc; Amgen Inc; Byondis BV; Dynavax Technologies Corp; Eisai Co Ltd; Eli Lilly and Co; Foundation for the National Institutes of Health Inc; G1 Therapeutics Inc; Genentech USA Inc; IQVIA Holdings Inc; Johnson & Johnson; Madrigal Pharmaceuticals Inc; Merck & Co Inc; Pfizer Inc; Plexxikon Inc; Puma Biotechnology Inc; Quantum Leap Health Care Collaborative; Regeneron Pharmaceuticals Inc; The Safeway Foundation | 4523; ABBV; AMAM; AMGN; DVAX; GTHX; IQV; JNJ; LLY; MDGL; MRK; PBYI; PFE; REGN | amcenestrant; ARX-788; cemiplimab; doxorubicin; encequidar mesylate + paclitaxel; fianlimab; ganitumab; lasofoxifene tartrate; MK-2206; neratinib; pembrolizumab; pexidartinib hydrochloride; SD-101; talazoparib; trastuzumab duocarmazine; trebananib; trilaciclib; veliparib ER | Oncology | Angiosarcoma; Breast Cancer; Breast Tumor; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Metastatic Breast Cancer; Triple-Negative Breast Cancer (TNBC) | Company Press Release |
| 26 Feb 2020 | PDUFA | Puma Biotechnology Inc | PBYI | neratinib | Oncology | Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) | Company Press Release |
| 31 Dec 2019 | Phase II Trial Results | Puma Biotechnology Inc; U.S. Department of Defence | PBYI | neratinib | Oncology | Breast Cancer; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer